NCT03975062 (RE-SOUND) is a Phase 4 clinical trial of dabigatran etexilate in Atrial Fibrillation, sponsored by Ural State Medical University.

Who is sponsoring NCT03975062?

NCT03975062 is sponsored by Ural State Medical University.

What drugs are being tested in NCT03975062?

Interventions in NCT03975062: dabigatran etexilate.

What condition does NCT03975062 study?

NCT03975062 studies Atrial Fibrillation.

Is NCT03975062 still recruiting?

NCT03975062 is currently status unknown. Last updated 5 June 2019.

Last reviewed 2019-06-05 · How we verify

NCT03975062: RE-SOUND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)

Status unknown Phase 4 Last updated 5 June 2019

What this trial tests

Phase 4 trial testing dabigatran etexilate in Atrial Fibrillation in 400 participants. Status unknown.

Timeline

28 December 2017

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Ural State Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	400
Start date	28 December 2017
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	1 location across Russia

Drugs / interventions tested

dabigatran etexilate (DABIGATRAN) — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Ural State Medical University

Who can join

Adults 19 to 74, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the efficacy of abbreviated 3-day anticoagulation with dabigatran etexilate before cardioversion guided by trans-oesophageal echocardiography in comparison with conventional 3- week course of dabigatran etexilate before cardioversion

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of dabigatran etexilate

Trials testing the same drug.

NCT06791187 — A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body · Phase 1 · completed
NCT03070171 — Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral A · Phase 1 · completed
NCT02239120 — Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ES · Phase 3 · completed
NCT02197416 — Safety of Dabigatran Etexilate in Blood Clot Prevention in Children · Phase 3 · completed
NCT01895777 — Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With V · Phase 3 · completed

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Ural State Medical University trials

Trials by the same sponsor.

NCT01270139 — Plasmonic Nanophotothermal Therapy of Atherosclerosis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03975062 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ural State Medical University
Last refreshed: 5 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing